Loading stock data…
Neuphoria Therapeutics Inc. (NEUP)
$4.40-0.17 (-3.72%)
After Hours$4.40+0.00 (+0.00%)· Last close Jun 29
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neuphoria Therapeutics Inc. in the Healthcare sector is trading at $4.40 with a market capitalization of $25M. The stock is currently near its 52-week low of $3.65, remaining 24.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $15.00M↑ | $662,715 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$827,284↑ | -$2.35M↑ | -$5.65M↓ | $11.97M↑ | -$3.40M |
| Net Income | -$505,063↓ | $1.86M↑ | -$9.91M↓ | $11.26M↑ | -$1.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$25.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.23%
Volume
Today's trading volume
122,379
Recent News
Scancell confirms advanced talks over reverse merger with Neuphoria
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of immunotherapies designed to treat cancer, has confirmed it is in advanced discussions over a reverse merger with US-listed Neuphoria Therapeutics. Responding to press speculation, the AIM-quoted company confirmed it is...
Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value?
Key Insights Neuphoria Therapeutics' estimated fair value is US$3.34 based on 2 Stage Free Cash Flow to Equity...
BC-Most Active Stocks
td class="col-issue">New Era Energy & Digital Inc.
Neuphoria scraps social anxiety hopeful after Phase III miss
Analysts from William Blair and GlobalData critiqued the trial design for social anxiety disorder, though the latter notes that BNC210 may have hope in PTSD.